Jan 26, 2022
- Fourth-quarter sales growth of 7.2 percent; organic sales growth of 7.7 percent
- Global COVID-19 testing-related sales of $2.3 billion in the fourth quarter
- Excluding COVID-19 testing-related sales, fourth-quarter sales growth of 9.6 percent and organic sales growth of 10.3 percent
- Full-year 2021 sales growth of 24.5 percent; organic sales growth of 22.9 percent
- Full-year 2021 GAAP diluted EPS from continuing operations growth of 58.2 percent; adjusted diluted EPS growth of 42.7 percent
- R&D pipeline continues to deliver a steady cadence of new products, including several in large, fast-growing markets